Abcam, a global leader in the supply of life science research tools, announced that it has entered into a definitive license agreement with Roche.
Under the terms of the agreement Abcam will obtain the exclusive rights to the product portfolio of Spring Bioscience Corporation in the research use only (RUO) field of use, comprising a total of approximately 760 unique products. Roche, which acquired Spring in 2007, will retain the antibody development capabilities and rights pertaining to the Spring Portfolio for internal research, companion diagnostic and IVD uses.
The core portfolio consists of 243 recombinant rabbit monoclonal antibodies, branded Spring Proprietary Clones (SP Clones), which have been optimised for immunohistochemistry (IHC). In addition to the SP Clones, the agreement covers approximately 500 additional products, predominantly other monoclonal and polyclonal antibodies. All products will be sold under the Abcam brand, inclusive of SP branding, and are expected to be available through Abcam from 21 February 2018.
Alan Hirzel, CEO, of Abcam said: “This agreement represents an exciting step in the ongoing collaborative and long-term relationship between Abcam and Roche. By incorporating the Spring Bioscience antibodies into our portfolio, we will be able to better assist our customers, providing them with more products for their most important targets, faster. Abcam is excited to partner with Spring Bioscience, commonly recognised as a leading manufacturer of IHC antibodies, furthering Abcam’s mission to provide customers with the highest quality recombinant antibodies for their research.”
Abcam, founded in 1998 and headquartered in Cambridge, UK, is an innovator in reagents and tools. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated biological binders and assays to address important targets in critical biological pathways.